Strategy & Approach

Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. We invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles.

Our venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile and attractive expected returns within three to five years from initial investment.

Longitude Capital seeks to identify new investment opportunities by tapping into our broad network of industry relationships

or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. We utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity and equity-linked instruments.

Following an initial investment, we work closely with our portfolio companies and syndicate partners to develop and implement strategic plans, achieve key operating objectives, build world class teams, raise capital and pursue liquidity opportunities in a manner that optimizes returns to key stakeholders.

Our company name was inspired by the Longitude Prize, a competition established by the British monarchy in 1714 to solve one of the greatest scientific problems of the day.

Our Team,
Your Partners

Longitude Capital’s founders have been investing together since 2002. Our team has over 150 years of combined investing experience in the life sciences industry and has collaborated on over 70 new investments and 150 follow-on investments in the biotechnology and medical technology sectors. We operate from our offices in Menlo Park, California and Greenwich, Connecticut.


Leadership


Sandip
Agarwala

Managing Director

Mr. Agarwala is a Managing Director of Longitude Capital focused on investments in biotechnology. Prior to joining Longitude Capital in 2013, Mr. Agarwala was a Vice President with Auven Therapeutics (formerly Celtic Therapeutics). Before joining Auven, he was a consultant in the healthcare practice at the Boston Consulting Group. Mr. Agarwala’s professional experience also includes various roles with Healthcare Royalty Partners, Paul Capital Partners and The Frankel Group, a boutique healthcare consulting firm. Mr. Agarwala holds an M.B.A. in Finance and Health Care Management from the Wharton School of Business at the University of Pennsylvania and a B.S.E. in Systems Engineering from the University of Pennsylvania. He has served on the board of directors of the Wharton Health Care Management Alumni Association.

Focus Areas: Royalty Investments, Biotechnology
Location: Greenwich

Juliet
Bakker

Managing Director

Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. She currently serves on the boards of Alphaeon, Calhoun Vision, Nalu and Venus Concept, and manages the firm’s investment in Encore Dermatology. She has previously served on the boards of Ablation Frontiers (acquired by Medtronic), AqueSys (acquired by Allergan), CryoVascular Systems (acquired by Boston Scientific), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R.Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), and Sadra Medical (acquired by Boston Scientific). Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University, where she also sits on the Business Advisory Committee of the Charles H. Dyson School of Applied Economics and Management and is a member of the President’s Council of Cornell Women.

Focus Areas: Medical Technology
Location: Greenwich

 

Patrick
Enright

Managing Director

Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience including senior executive positions at Valentis (VLTS), Boehringer Mannheim Pharmaceuticals and Sandoz. Mr. Enright currently serves on the boards of Aimmune (AIMT), Aptinyx, CardioDx, Corcept Therapeutics (CORT), CrownWheel Partners, InfaCare Pharmaceuticals, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics and SutroVax. Selected prior board memberships include Codexis (CDXS), Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Ovation), Sequenom (SQNM) and Threshold Pharmaceuticals (THLD). Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.

Focus Areas: Biotechnology, Royalty Investments
Location: Menlo Park

Marc
Galletti

Managing Director

Mr. Galletti is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Galletti was a Senior Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund Management and the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals. Mr. Galletti recently sat on the boards of Aptus Endosystems (acquired by Medtronic) and Twelve (acquired by Medtronic). He has also been involved with prior investments in Ablation Frontiers (acquired by Medtronic), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Ovation), Sadra Medical (acquired by Boston Scientific) and Threshold Pharmaceuticals (THLD). Mr. Galletti sits or has sat on advisory boards for the Innovation and New Ventures Office at Northwestern University, the Program for Biomedical Engineering at Brown University, the Venture Capital Advisory Board of AdvaMed and the Life Sciences Advisory Board of Silicon Valley Bank. Mr. Galletti holds an M.B.A. in Finance and Health Services Management from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.

Focus Areas: Medical Technology, Thematic Research
Location: Menlo Park

Gregory
Grunberg

Managing Director

Dr. Grunberg is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2012, Dr. Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with UCSF and Kaiser Permanente. Dr. Grunberg currently serves on the board of BAROnova, California Cryobank and Kala Pharmaceuticals, and manages the firm’s investment in Practice Fusion. He formerly served on the board of AqueSys (acquired by Allergan) and was a board observer at SARCode Bioscience (acquired by Shire) while at Rho Ventures. Dr. Grunberg holds an M.D. and an M.B.A from Duke University where he was a Fuqua Scholar and an A.B. in Economics and English from Amherst College.

Focus Areas: Medical Technology
Location: Menlo Park

Carolyn
Helms

Chief Financial Officer and Chief Compliance Officer

Ms. Helms is the Chief Financial Officer and Chief Compliance Officer at Longitude Capital. Prior to joining Longitude Capital in 2008, Ms. Helms was the Controller at Sierra Ventures, a technology-focused venture capital firm with over $1.5 billion under management. At Sierra Ventures, Ms. Helms managed the finance staff and was responsible for all aspects of financial accounting, reporting and tax. Prior to Sierra Ventures, Ms. Helms held the position of Accounting Manager at NetManage, a publicly-traded software company, and was a Senior Auditor with Arthur Andersen LLP. Ms. Helms is a licensed C.P.A. (inactive) and graduated cum laude with a B.S. in Business Administration (Accounting) from San Jose State University.

Focus Areas: Finance, Compliance
Location: Menlo Park

David
Hirsch

Managing Director

Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical (COLL), Rapid Micro Biosystems, Tricida, Velicept and Zavante Therapeutics. Previous boards include Civitas Therapeutics (acquired by Acorda) and Precision Therapeutics. Dr. Hirsch also led Longitude Capital’s investments in Amarin (AMRN) and Cadence Pharmaceuticals (CADX). Dr. Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a B.A. in Biology from The Johns Hopkins University.

Focus Areas: Biotechnology
Location: Greenwich


Investment Professionals


Derek
Abel

Associate

Mr. Abel is an Associate at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Abel was an analyst on the investment team at HealthCare Royalty Partners. Mr. Abel holds a B.S.B.A in Finance and Healthcare Management from Washington University in St. Louis.

Focus Areas: Royalty Investments, Biotechnology
Location: Greenwich

Perry
Clarkson

Associate

Mr. Clarkson is an Associate at Longitude Capital. Prior to joining Longitude Capital in 2013, Mr. Clarkson was an M&A analyst in the Healthcare Investment Banking group of Barclays. Mr. Clarkson holds a B.A.S. in Biomedical Science and a B.S.E. in Economics with a concentration in Finance from the University of Pennsylvania.

Focus Areas: Biotechnology, Royalty Investments
Location: Greenwich

Reinaldo
Diaz

Venture Partner

Mr. Diaz is a Venture Partner of Longitude Capital. Concurrent with his position with Longitude Capital, Mr. Diaz is also Managing Director of Auven Therapeutics. Prior to joining Auven Therapeutics, he was a Managing Member and co-founder of Diaz & Altschul Capital Management (D&A Capital). Prior to founding D&A Capital, Mr. Diaz was Managing Director and Head of the Healthcare group at Schroder Wertheim & Co. Mr. Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation. Mr. Diaz holds an M.B.A. from Harvard Business School and a B.A. from Harvard University.

Focus Areas: Royalty Investments, Biotechnology
Location: Greenwich

Andrew
Elbardissi

Principal

Dr. ElBardissi is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2014, Dr. ElBardissi was an Associate in J.P. Morgan’s Healthcare Investment Banking practice. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi is a board observer at Alphaeon and Calhoun Vision, and has been actively involved with Longitude Capital’s investment in California Cryobank. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Focus Areas: Medical Technology
Location: Menlo Park

Dylan
Harmon

Senior Analyst

Mr. Harmon is a Senior Analyst at Longitude Capital. Prior to joining Longitude Capital in 2015, Mr. Harmon was an M&A analyst in the Healthcare Investment Banking group of Bank of America Merrill Lynch. Mr. Harmon holds a B.S. in Applied Economics and Management from Cornell University.

Focus Areas: Biotechnology
Location: Greenwich

Oren
Isacoff

Vice President

Dr. Isacoff is a Vice President at Longitude Capital. Prior to joining Longitude Capital in 2015, Dr. Isacoff was a Senior Associate in the Healthcare Team of TPG Special Situations Partners. Dr. Isacoff completed his internship at Massachusetts General Hospital and maintains an active medical license. Dr. Isacoff is a board observer at Velicept Therapeutics and Zavante Therapeutics. Dr. Isacoff holds an M.D. and an M.B.E. from the Perelman School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Political Science and B.S. in Economics from the University of Pennsylvania.

Focus Areas: Biotechnology
Location: Greenwich

Shaun
Mehra

Senior Analyst

Mr. Mehra is a Senior Analyst at Longitude Capital.  Prior to joining Longitude Capital in 2016, Mr. Mehra was an Analyst at Silver Lake Partners, a large cap technology private equity firm, and an investment banking analyst at Goldman Sachs before that.  Mr. Mehra holds a B.S. in Economics from the Wharton School and a B.S. in Bioengineering with minors in Biophysics and Mathematics from the University of Pennsylvania.

Focus Areas: Medical Technology
Location: Menlo Park

Josh
Richardson

Principal

Dr. Richardson is a Principal at Longitude Capital. Dr. Richardson was previously with Longitude Capital from 2011 to 2014, and prior to re-joining Longitude Capital in 2016, Dr. Richardson was a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments. Prior to joining Longitude in 2011, Dr. Richardson was an Engagement Manager with McKinsey & Company. Dr. Richardson is a board observer at InfaCare Pharmaceuticals, and was involved with a number of Longitude investments including Aimmune Therapeutics (AIMT), Collegium Pharmaceuticals (COLL), Cadence Pharmaceuticals (CADX, acquired by Mallinckrodt) and Precision Dermatology (acquired by Valeant Pharmaceuticals). Dr. Richardson holds an M.D. from the University of Virginia and a B.S. in biomedical science from the University of South Florida.

Focus Areas: Biotechnology
Location: Greenwich

Allyson
Rinderle

Vice President

Ms. Rinderle is a Vice President at Longitude Capital. Prior to joining Longitude Capital in 2016, and prior to completing her M.B.A, Ms. Rinderle was an Analyst at Aisling Capital, a multi-strategy healthcare investment firm based in New York. Ms. Rinderle started her career as an Analyst in J.P. Morgan’s Healthcare Investment Banking practice. Ms. Rinderle is a board observer at SutroVax. Ms. Rinderle holds an M.B.A from Stanford Graduate School of Business, where she was an Arjay Miller Scholar. She received her B.S. in Biomedical Engineering with distinction from Yale University, graduating magna cum laude, Tau Beta Pi, and Phi Beta Kappa.

Focus Areas: Biotechnology
Location: Menlo Park


Operations


Stephanie
Holman

Senior Fund Accountant

Ms. Holman is a Fund Accountant at Longitude Capital. Prior to joining Longitude in 2013, Ms. Holman was an Audit Associate with Moss Adams LLP and PricewaterhouseCoopers LLP, where she served technology and life sciences companies, as well as venture capital firms. Ms. Holman holds a B.S. in Microbiology from San Jose State University and a Certificate of Advanced Accounting Proficiency from Santa Clara University.

Location: Menlo Park

Nicole
Hughes

Executive Assistant

Ms. Hughes is an Executive Assistant at Longitude Capital supporting both the Biotechnology and Medical Technology teams. Prior to joining Longitude Capital in 2007, Ms. Hughes was an Executive Assistant at Pequot Ventures. Previously, Ms. Hughes served as an Executive Assistant at Pollock Financial Group. Ms. Hughes holds a B.A. in Sociology from Menlo College.

Location: Menlo Park

Karen
Lok

Controller

Ms. Lok is the Controller at Longitude Capital. Prior to joining Longitude Capital in 2015, Ms. Lok spent seven years at KPMG LLP (formerly Rothstein Kass) in audit and assurance, with a focus in life sciences venture capital funds. Ms. Lok holds a B.A. in Economics with emphasis in Accounting from University of California Santa Barbara.

Location: Menlo Park

Allison
London

Executive Assistant

Ms. London is an Executive Assistant at Longitude Capital supporting the Medical Technology and Investor Relations and Marketing teams. Prior to joining Longitude Capital in 2015, Ms. London was an Executive Assistant for the Whitfield Group at Morgan Stanley Private Wealth Management. Previously, Ms. London served as Senior Executive Assistant to the Head of Northern California at JP Morgan Private Bank. Ms. London spent her prior years at Paramount Pictures where she managed Advertising and Promotion for Network and Syndicated Television. Ms. London holds a B.A. in Journalism and Mass Communication from the University of Minnesota.

Location: Menlo Park

Dinorah
Martinez

Executive Assistant

Ms. Martinez is an Executive Assistant at Longitude Capital supporting both the Biotechnology and Medical Technology teams. Prior to joining Longitude in 2011, Ms. Martinez worked at Tudor Investments, supporting the Emerging Markets group. Previously, she worked in the operations department of Silver Point Capital. Ms. Martinez holds a B.S.L.I. in Linguistics from Georgetown University.

Location: Greenwich

Michaela
Parnell

Investor Relations Associate

Ms. Parnell is an Investor Relations and Marketing Associate at Longitude Capital. Prior to joining Longitude Capital in 2015, Ms. Parnell was a Senior Account Executive at MacDougall Biomedical Communications, a life sciences communications consultancy. Prior to joining MacDougall, she was an Associate at the Trout Group, a boutique investor relations and strategic advisory firm. Ms. Parnell holds a B.A. in Economics and International Relations from William Smith College.

 

Location: Menlo Park

Elliot
Shih

Fund Accountant

Mr. Shih is a Fund Accountant at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Shih was the Director of Finance and Accounting at Founder.org, where he was responsible for accounting and financial operations. Prior to Founder.org, Mr. Shih was a Tax Senior Associate at PricewaterhouseCoopers LLP, where he served hedge funds, mutual funds, private equity firms and venture capital firms. Mr. Shih is a licensed C.P.A. and holds a B.A. in Economics from the University of California, Berkeley.

 


Location: Menlo Park

Investing in Healthcare Innovation

Longitude Capital invests in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system cost. From start-ups to growth equity investments, we are dedicated to helping management teams achieve technical, clinical and commercial milestones to create value and deliver attractive returns to our limited partners.

Portfolio


News

Check out the latest news about Longitude Capital and our portfolio companies.

Contact Us

Menlo Park, California

800 El Camino Real, Ste. 220
Menlo Park, CA 94025
650.854.5700
Click here for directions

Greenwich, Connecticut

One Fawcett Place
Greenwich, CT 06830
203.769.5200
Click here for directions